Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

High Blood Pressure and Cardiovascular Prevention

Volumn 19, Issue 4, 2012, Pages 237-244

  Volpe, Massimo ^a   Agabiti Rosei, Enrico ^b   Ambrosioni, Ettore ^c   Cottone, Santina ^d   Cuspidi, Cesare ^e   Borghi, Claudio ^c   De Luca, Nicola ^f   Fallo, Francesco ^g   Ferri, Claudio ^h   Mancia, Giuseppe ^e   Morganti, Alberto ⁱ   Muiesan, Maria Lorenza ^b   Sarzani, Riccardo ^j   Sechi, Leonardo ^k   Tocci, Giuliano ^a   Virdis, Agostino ^l  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF L'AQUILA   (Italy)

ⁱ San Giuseppe Hospital   (Italy)

^j University of Marche   (Italy)

^k UNIVERSITY OF UDINE   (Italy)

^l UNIVERSITY OF PISA   (Italy)

more..

Author keywords

Hypertension, treatment; Resistant hypertension, treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DENERVATION; ESSENTIAL HYPERTENSION; HUMAN; LIFESTYLE MODIFICATION; MORBIDITY; PATIENT SELECTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RENAL ARTERY; RESISTANT HYPERTENSION; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CATHETER ABLATION; DRUG RESISTANCE; HUMANS; HYPERTENSION; PATIENT SELECTION; RENAL ARTERY; RISK ASSESSMENT; RISK FACTORS; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84877874143     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/BF03297636     Document Type: Article

References (52)

1. Staessen JA, Wang J, Bianchi G, et al. Essential hypertension. Lancet 2003 May 10; 361 (9369) 1629-41
2. Staessen JA Wang J Bianchi G et al. Essential hypertension Lancet 2003 May 10 361 9369 1629-41
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349) 1903-13
4. Lewington S Clarke R Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 2002 Dec 14 360 9349 1903-13
5. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007 Dec 1; 370 (9602) 1829-39
6. Lewington S Whitlock G Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 2007 Dec 1 370 9602 1829-39
7. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165 (12) 1410-9
8. Turnbull F Neal B Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus results of prospectively designed overviews of randomized trials Arch Intern Med 2005 Jun 27 165 12 1410-9
9. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults meta-analysis of randomised trials. BMJ 2008 May 17; 336 (7653) 1121-3
10. Turnbull F Neal B Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults meta-analysis of randomised trials BMJ 2008 May 17 336 7653 1121-3
11. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395) 1527-35
12. Turnbull F Effects of different blood-pressure-lowering regimens on major cardiovascular events results of prospectively-designed overviews of randomised trials Lancet 2003 Nov 8 362 9395 1527-35
13. Zanchetti A, Mancia G, Black HR, et al. Facts and fallacies of blood pressure control in recent trials implications in the management of patients with hypertension. J Hypertens 2009 Apr; 27 (4) 673-9
14. Zanchetti A Mancia G Black HR et al. Facts and fallacies of blood pressure control in recent trials implications in the management of patients with hypertension J Hypertens 2009 Apr 27 4 673-9
15. Bramlage P, Bohm M, Volpe M, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) 2010 Sep; 12 (9) 666-77
16. Bramlage P Bohm M Volpe M et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients J Clin Hypertens (Greenwich) 2010 Sep 12 9 666-77
17. Dallongeville J, Banegas JR, Tubach F, et al. Survey of physicians' practices in the control of cardiovascular risk factors the EURIKA study. Eur J Prev Cardiol 2012 Jun; 19 (3) 541-50
18. Dallongeville J Banegas JR Tubach F et al. Survey of physicians' practices in the control of cardiovascular risk factors the EURIKA study Eur J Prev Cardiol 2012 Jun 19 3 541-50
19. Prugger C, Keil U, Wellmann J, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe results from the EUROASPIRE III survey. J Hypertens 2011 Aug; 29 (8) 1641-8
20. Prugger C Keil U Wellmann J et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe results from the EUROASPIRE III survey J Hypertens 2011 Aug 29 8 1641-8
21. Chobanian AV. Shattuck Lecture. The hypertension paradox more uncontrolled disease despite improved therapy. N Engl J Med 2009 Aug 27; 361 (9) 878-87
22. Chobanian AV Shattuck Lecture. The hypertension paradox more uncontrolled disease despite improved therapy N Engl J Med 2009 Aug 27 361 9 878-87
23. Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy results of recent surveys on hypertension. J Hypertens 2007 Jul; 25 (7) 1491-8
24. Volpe M Tocci G Trimarco B et al. Blood pressure control in Italy results of recent surveys on hypertension J Hypertens 2007 Jul 25 7 1491-8
25. Tocci G, Rosei EA, Ambrosioni E, et al. Blood pressure control in Italy analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens 2012 Jun; 30 (6) 1065-74
26. Tocci G Rosei EA Ambrosioni E et al. Blood pressure control in Italy analysis of clinical data from 2005-2011 surveys on hypertension J Hypertens 2012 Jun 30 6 1065-74
27. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25 (9) 1751-62
28. Mancia G De Backer G Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension ESH-ESC Task Force on the Management of Arterial Hypertension J Hypertens 2007 Sep 25 9 1751-62
29. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 Apr; 49 (4) 839-45
30. Chapman N Dobson J Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 2007 Apr 49 4 839-45
31. Volpe M, Tocci G. Challenging hypertension how to diagnose and treat resistant hypertension in daily clinical practice. Expert Rev Cardiovasc Ther 2010 Jun; 8 (6) 811-20
32. Volpe M Tocci G Challenging hypertension how to diagnose and treat resistant hypertension in daily clinical practice Expert Rev Cardiovasc Ther 2010 Jun 8 6 811-20
33. Sarafidis PA, Bakris GL. Resistant hypertension an overview of evaluation and treatment. J Am Coll Cardiol 2008 Nov 25; 52 (22) 1749-57
34. Sarafidis PA Bakris GL Resistant hypertension an overview of evaluation and treatment J Am Coll Cardiol 2008 Nov 25 52 22 1749-57
35. Schmieder RE, Redon J, Grassi G, et al. ESH position paper renal denervatioN-an interventional therapy of resistant hypertension. J Hypertens 2012 May; 30 (5) 837-41
36. Schmieder RE Redon J Grassi G et al. ESH position paper renal denervatioN-an interventional therapy of resistant hypertension J Hypertens 2012 May 30 5 837-41
37. Schlaich MP, Krum H, Sobotka PA, et al. Renal denervation and hypertension. Am J Hypertens 2011 Jun; 24 (6) 635-42
38. Schlaich MP Krum H Sobotka PA et al. Renal denervation and hypertension Am J Hypertens 2011 Jun 24 6 635-42
39. Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension novel implications for an old concept. Hypertension 2009 Dec; 54 (6) 1195-201
40. Schlaich MP Sobotka PA Krum H et al. Renal denervation as a therapeutic approach for hypertension novel implications for an old concept Hypertension 2009 Dec 54 6 1195-201
41. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension a multicentre safety and proof-of-principle cohort study. Lancet 2009 Apr 11; 373 (9671) 1275-81
42. Krum H Schlaich M Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension a multicentre safety and proof-of-principle cohort study Lancet 2009 Apr 11 373 9671 1275-81
43. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 trial) a randomised controlled trial. Lancet 2010 Dec 4; 376 (9756) 1903-9
44. Esler MD Krum H Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 trial) a randomised controlled trial Lancet 2010 Dec 4 376 9756 1903-9
45. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23 (7) 1250-7
46. Hering D Mahfoud F Walton AS et al. Renal denervation in moderate to severe CKD J Am Soc Nephrol 2012 23 7 1250-7
47. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003 May; 21 (5) 821-48
48. O'Brien E Asmar R Beilin L et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement J Hypertens 2003 May 21 5 821-48
49. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension durability of blood pressure reduction out to 24 months. Hypertension 2011 May; 57 (5) 911-7
50. Symplicity HTN-1 Investigators Catheter-based renal sympathetic denervation for resistant hypertension durability of blood pressure reduction out to 24 months Hypertension 2011 May 57 5 911-7
51. Schmieder RE, Redon J, Grassi G, et al. ESH Position paper renal denervation – an interventional therapy of resistant hypertension. J Hypertens 2012 May; 30 (5) 837-41
52. Schmieder RE Redon J Grassi G et al. ESH Position paper renal denervation – an interventional therapy of resistant hypertension J Hypertens 2012 May 30 5 837-41